30338926|t|Advanced glycation end products-related modulation of cathepsin L and NF-kappaB signalling effectors in retinal pigment epithelium lead to augmented response to TNFalpha.
30338926|a|The retinal pigment epithelium (RPE) plays a central role in neuroretinal homoeostasis throughout life. Altered proteolysis and inflammatory processes involving RPE contribute to the pathophysiology of age-related macular degeneration (AMD), but the link between these remains elusive. We report for the first time the effect of advanced glycation end products (AGE)-known to accumulate on the ageing RPE's underlying Bruch's membrane in situ-on both key lysosomal cathepsins and NF-kappaB signalling in RPE. Cathepsin L activity and NF-kappaB effector levels decreased significantly following 2-week AGE exposure. Chemical cathepsin L inhibition also decreased total p65 protein levels, indicating that AGE-related change of NF-kappaB effectors in RPE cells may be modulated by cathepsin L. However, upon TNFalpha stimulation, AGE-exposed cells had significantly higher ratio of phospho-p65(Ser536)/total p65 compared to non-AGEd controls, with an even higher fold increase than in the presence of cathepsin L inhibition alone. Increased proportion of active p65 indicates an AGE-related activation of NF-kappaB signalling in a higher proportion of cells and/or an enhanced response to TNFalpha. Thus, NF-kappaB signalling modulation in the AGEd environment, partially regulated via cathepsin L, is employed by RPE cells as a protective (para-inflammatory) mechanism but renders them more responsive to pro-inflammatory stimuli.
30338926	0	31	Advanced glycation end products	Chemical	MESH:D017127
30338926	54	65	cathepsin L	Gene	1514
30338926	70	79	NF-kappaB	Gene	4790
30338926	161	169	TNFalpha	Gene	7124
30338926	203	206	RPE	CellLine	CVCL:IQ82
30338926	299	311	inflammatory	Disease	MESH:D007249
30338926	332	335	RPE	CellLine	CVCL:IQ82
30338926	373	405	age-related macular degeneration	Disease	MESH:D008268
30338926	407	410	AMD	Disease	MESH:D008268
30338926	500	531	advanced glycation end products	Chemical	MESH:D017127
30338926	572	575	RPE	CellLine	CVCL:IQ82
30338926	636	646	cathepsins	Gene	1520
30338926	651	660	NF-kappaB	Gene	4790
30338926	675	678	RPE	CellLine	CVCL:IQ82
30338926	680	691	Cathepsin L	Gene	1514
30338926	705	714	NF-kappaB	Gene	4790
30338926	795	806	cathepsin L	Gene	1514
30338926	839	842	p65	Gene	5970
30338926	897	906	NF-kappaB	Gene	4790
30338926	920	923	RPE	CellLine	CVCL:IQ82
30338926	950	962	cathepsin L.	Gene	1514
30338926	977	985	TNFalpha	Gene	7124
30338926	1059	1062	p65	Gene	5970
30338926	1077	1080	p65	Gene	5970
30338926	1170	1181	cathepsin L	Gene	1514
30338926	1231	1234	p65	Gene	5970
30338926	1274	1283	NF-kappaB	Gene	4790
30338926	1358	1366	TNFalpha	Gene	7124
30338926	1374	1383	NF-kappaB	Gene	4790
30338926	1455	1466	cathepsin L	Gene	1514
30338926	1483	1486	RPE	CellLine	CVCL:IQ82
30338926	1515	1527	inflammatory	Disease	MESH:D007249
30338926	1579	1591	inflammatory	Disease	MESH:D007249
30338926	Positive_Correlation	MESH:D017127	7124
30338926	Association	MESH:D017127	4790
30338926	Association	4790	7124
30338926	Association	MESH:D017127	1520
30338926	Association	MESH:D017127	1514
30338926	Negative_Correlation	1514	5970
30338926	Association	1514	4790
30338926	Positive_Correlation	5970	7124
30338926	Association	1514	7124

